<DOC>
	<DOCNO>NCT01797874</DOCNO>
	<brief_summary>To evaluate efficacy pazopanib maintenance 1st line CTx SCLC .</brief_summary>
	<brief_title>Pazopanib Maintenance SCLC</brief_title>
	<detailed_description />
	<criteria>histologically confirm SCLC disease progression 4 cycle etoposide/platinum 1stline therapy history 4 cycle etoposide/platinum 1stline therapy 21 day 42 day since C4D1 etoposide/platinum symptomatic brain meta poor hepatic , renal function</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pazopanib maintenance</keyword>
	<keyword>efficacy</keyword>
	<keyword>SCLC</keyword>
</DOC>